

- Amendments to the Specification -

Immediately after the title of the application, please insert the following:


-- CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority under 37 C.F.R. §1.78(a)(3) of United States Provisional Patent Application Number 60/265,304, filed January 31, 2001. --

After the last page of the claims, add the following abstract:

-- ABSTRACT OF THE INVENTION

This application is directed to compounds of the formula



wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W¹ and W² are independently -O- or -S(=O)_t-, where t is 0, 1, or 2; Y is =C(R¹_a)-, where R¹_a is a member selected from the group consisting of H; F; Cl; CN; NO₂; -(C₁-C₄) alkyl; -(C₂-C₄) alkynyl; fluorinated-(C₁-C₃) alkyl; fluorinated-(C₁-C₃) alkoxy; -OR¹⁶; and -C(=O)NR²²_aR²²_b; R²²_a and R²²_b are defined as set forth in the specification; -R^A and R^B are each a member independently selected from the group consisting of H; F; CF₃; -(C₁-C₄) alkyl; -(C₃-C₇) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R¹⁰, which is defined as set forth in the specification; R¹⁶ and R¹⁷ are defined as set forth in the specification; -R^C and R^D have the same meaning as defined above for R^A and R^B except that one of them must be -H, and they are selected independently of each other and of R^A and R^B; R¹ and R² are each a member independently selected from the group consisting of H; F; Cl; CN; NO₂; -(C₁-C₄) alkyl; -(C₂-C₄) alkynyl; fluorinated-(C₁-C₃)alkyl; OR¹⁶; and -C(=O)NR²²_aR²²_b; -R³ is H; -(C₁-C₃)alkyl; phenyl; benzyl; or OR¹⁶; R⁴, R⁵ and R⁶ are defined as set forth in the specification; J¹ and J² are each independently a moiety comprising a saturated or unsaturated six-membered monocyclic carbon ring; and D is a member independently selected from the group consisting of partial Formulas (1.1.1) through (1.1.5) as set forth in the specification; a pharmaceutically acceptable salt thereof; which are useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease. --

Applicants have enclosed a copy of the abstract on a separate page herewith, consecutively numbered with the last page of the claims.